Biotherapharma_logo.jpg
Biothera Pharmaceuticals to Present Clinical Data from Phase 2 Triple Negative Breast Cancer Study at ASCO 2019 Annual Meeting
16 mai 2019 10h00 HE | Biothera Pharmaceuticals, Inc.
EAGAN, Minn., May 16, 2019 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc., which is developing a dectin receptor agonist drug known as Imprime PGG, announced today that it will present primary...
Biotherapharma_logo.jpg
Preclinical Data Showing Synergy of Biothera Pharmaceuticals’ Imprime PGG and a CD40 Agonist in a Pancreatic Cancer Model Presented at Keystone Symposia
26 mars 2018 10h00 HE | Biothera Pharmaceuticals, Inc.
EAGAN, Minn., March 26, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. and the Abramson Cancer Center of the University of Pennsylvania announced today the presentation of new preclinical...
Biotherapharma_logo.jpg
Biothera Announces Three Presentations at Upcoming American Association for Cancer Research (AACR) Annual Meeting
27 mars 2017 11h00 HE | Biothera Pharmaceuticals, Inc.
EAGAN, Minn., March 27, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals Inc. announced today that it will present three scientific posters at the American Association for Cancer Research (AACR)...